Clinical trial · Interventional
Efficacy and Safety of Patupilone in Patients With Advanced Solid Tumors in Japan
A Phase IA, Open-label, Dose Escalation Study of Patupilone Administered Intravenously Every 3 Weeks in Adult Patients With Advanced Solid Tumors
NCT00412789CI-TRIAL-00003498completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study will evaluate the safety and efficacy of Patupilone in adult patients with advanced solid tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Tumors | Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patupilone | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- EPO906
- interventionNames
- Drug: Patupilone
Primary outcomes (1)
- measure
- Dose-limiting Toxicity
- timeFrame
- 18 months
Secondary outcomes (3)
- measure
- Safety and tolerability of patupilone assessed by CTCAE
- timeFrame
- 18 months
- measure
- Pharmacokinetic profile of patupilone
- timeFrame
- 18 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion criteria: * Patients with a histologically/cytologically confirmed diagnosis of advanced solid tumors refractory to or unsuitable for standard therapy, or for whom no standard therapy exists * Patients with WHO Performance Status of 0-1 ( Karnofsky Performance Status of 80-100) * At least one measurable lesion Exclusion criteria: * Patients with any peripheral neuropathy * Patients with unresolved diarrhea * Patients with severe and/or uncontrolled medical conditions or infections that require systemic therapy Other protocol-defined inclusion/exclusion criteria may apply
References
Publications (0)
Data not yet available
No reference posted for this study.